Leerink Partnrs Has Negative Outlook of BMY Q2 Earnings

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Research analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for shares of Bristol-Myers Squibb in a research note issued to investors on Friday, April 25th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $1.69 per share for the quarter, down from their prior estimate of $1.74. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol-Myers Squibb's Q3 2025 earnings at $1.69 EPS, Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $6.98 EPS, FY2027 earnings at $6.07 EPS, FY2028 earnings at $5.58 EPS and FY2029 earnings at $6.08 EPS.

Other equities analysts also recently issued reports about the stock. Truist Financial increased their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Piper Sandler initiated coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. UBS Group lowered their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Trading Down 1.3 %

Bristol-Myers Squibb stock traded down $0.67 during mid-day trading on Monday, reaching $49.53. 17,161,789 shares of the company traded hands, compared to its average volume of 12,974,696. The firm's 50 day moving average price is $55.99 and its 200 day moving average price is $56.41. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm has a market capitalization of $100.79 billion, a price-to-earnings ratio of -11.21, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter last year, the business posted ($4.40) EPS. The business's revenue was down 5.6% on a year-over-year basis.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.01%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bristol-Myers Squibb

Several hedge funds have recently bought and sold shares of BMY. Vanguard Group Inc. lifted its position in shares of Bristol-Myers Squibb by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock valued at $10,743,262,000 after acquiring an additional 1,373,209 shares in the last quarter. Capital International Investors raised its holdings in Bristol-Myers Squibb by 7.5% in the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after acquiring an additional 3,218,865 shares in the last quarter. Geode Capital Management LLC raised its holdings in Bristol-Myers Squibb by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after acquiring an additional 1,187,231 shares in the last quarter. Norges Bank bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at $1,989,525,000. Finally, Ameriprise Financial Inc. increased its stake in Bristol-Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.